Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Nanotechnology ; 33(42)2022 Jul 29.
Article in English | MEDLINE | ID: mdl-35830829

ABSTRACT

Combining novel two-dimensional materials with traditional semiconductors to form heterostructures for photoelectric detection have attracted great attention due to their excellent photoelectric properties. In this study, we reported the formation of a heterostructure comprising of tin telluride (SnTe) and germanium (Ge) by a simple and efficient one-step magnetron sputtering technique. A photodetector was fabricated by sputtering a nanofilm of SnTe on to a pre-masked n-Ge substrate.J-Vmeasurements obtained from the SnTe/n-Ge photodetector demonstrated diode and photovoltaic characteristics in the visible to near-infrared (NIR) band (i.e. 400-2050 nm). Under NIR illumination at 850 nm with an optical power density of 13.81 mW cm-2, the SnTe/n-Ge photodetector exhibited a small open-circuit voltage of 0.05 V. It also attained a high responsivity (R) and detectivity (D*) of 617.34 mA W-1(at bias voltage of -0.5 V) and 2.33 × 1011cmHz1/2W-1(at zero bias), respectively. Therefore, SnTe nanofilm/n-Ge heterostructure is highly suitable for used as low-power broadband photodetector due to its excellent performances and simple device configuration.

2.
Front Pharmacol ; 8: 545, 2017.
Article in English | MEDLINE | ID: mdl-28860994

ABSTRACT

Pioglitazone is a type of peroxisome proliferator-activated receptor γ (PPARγ) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment. However, the underlying mechanism involved in the renoprotection of pioglitazone has not been fully revealed. In the present study, the renoprotective mechanism of pioglitazone was investigated in 5/6 nephrectomized (Nx) rats and TGF-ß1-exposed HK-2 cells. Pioglitazone attenuated renal injury and improved renal function, as examined by 24 h urinary protein, blood urea nitrogen and plasma creatinine in Nx rats. Renal fibrosis and enhanced expressions of profibrotic proteins TGF-ß1, fibronectin and collagen I caused by Nx were significantly alleviated by pioglitazone. In addition, pioglitazone protected mitochondrial functions by stabilizing the mitochondrial membrane potential, inhibiting ROS generation, maintaining ATP production and the activities of complexes I and III, and preventing cytochrome C leakage from mitochondria. Pioglitazone also upregulated the expression levels of ATP synthase ß, COX I and NDUFB8, which were downregulated in the kidney of Nx rats and TGF-ß1-exposed HK-2 cells. Furthermore, pioglitazone increased fusion proteins Opa-1 and Mfn2 expressions and decreased fission protein Drp1 expression. The results imply that pioglitazone may exert the renoprotective effects through modulating mitochondrial electron transport chain and mitochondrial dynamics in CKD. Finally, these recoveries were completely or partly inhibited by GW9662, which suggests that these effects at least partly PPARγ dependent. This study provides evidence for the pharmacological mechanism of pioglitazone in the treatment of CKD.

3.
Biotechnol Lett ; 39(8): 1159-1166, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28470626

ABSTRACT

OBJECTIVES: To investigate the potential of interleukin (IL)-15 as a novel adjuvant for Mycobacterium tuberculosis (Mtb) antigen 85A (Ag85A) vaccine. RESULTS: C57BL/6 mice were intramuscularly immunized three times with a plasmid expressing the Ag85A-IL-15 fusion protein (pcDNA3.1-Ag85A-IL-15), with the empty pcDNA3.1 vector and the pcDNA3.1-Ag85A as control. Mice vaccinated with pcDNA3.1-Ag85A-IL-15 generated more secretory IgA (sIgA) into their lung (209 ± 21 µg/ml) and acquired an enhanced serum IgG response to Ag85A. IgG2a/IgG1 ratios were upregulated, natural killer cell activity was augmented and Ag85A-specific splenic T cell proliferation was enhanced in these mice as well. Vaccination with pcDNA3.1-Ag85A-IL-15 promoted the polarization of CD4+ T cells towards a Th1 type in the spleen, and significantly upregulated the serum level of interferon (IFN)-γ (458 ± 98 pg/ml), a typical Th1 cytokine. IFN-γ-expressing CD8+ cells were also increased in the spleen after pcDNA3.1-Ag85A-IL-15 immunization. CONCLUSIONS: A superior immune type I response in mice vaccinated with plasmid Ag85A-IL-15 has been achieved.


Subject(s)
Acyltransferases/immunology , Adjuvants, Immunologic , Antigens, Bacterial/immunology , Interferon-gamma/immunology , Recombinant Fusion Proteins/immunology , Tuberculosis Vaccines/immunology , Vaccines, DNA/immunology , Acyltransferases/chemistry , Acyltransferases/genetics , Adjuvants, Immunologic/chemistry , Adjuvants, Immunologic/genetics , Animals , Antigens, Bacterial/chemistry , Antigens, Bacterial/genetics , Bronchoalveolar Lavage Fluid/cytology , Cells, Cultured , Cloning, Molecular , HEK293 Cells , Humans , Interferon-gamma/chemistry , Interferon-gamma/genetics , Mice , Mice, Inbred C57BL , Plasmids , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Spleen/cytology , Tuberculosis , Tuberculosis Vaccines/chemistry , Tuberculosis Vaccines/genetics , Vaccines, DNA/chemistry , Vaccines, DNA/genetics
4.
Cell Physiol Biochem ; 38(5): 1831-40, 2016.
Article in English | MEDLINE | ID: mdl-27160248

ABSTRACT

BACKGROUND/AIMS: Pioglitazone is a type of peroxisome proliferator-activated receptor x03B3; agonist and is capable of alleviating renal ischemia-reperfusion injury. METHODS: A5/6 nephrectomized rat model was established to induce renal impairments mimicking chronic kidney diseases (CKDs). The effect of pioglitazone on renal structure, function, antioxidative capacity, and angiogenesis in the nephrectomized rats was assessed. Moreover, the expression of HIF-1α, eNOS, VEGF, Flt-1 and Flk-1 was determined to reveal the possible pathways through which pioglitazone exerted its beneficial effect on CKDs. RESULTS: Subtotal nephrectomy caused severe damages to rat renal tissues, and administration of pioglitazone dramatically restored the structure and function of the kidney, which was evidenced by Periodic acid- Schiff staining and the reduced levels of urinary proteins, blood urea nitrogen, and creatinine. Furthermore, pioglitazone decreased the level of malondialdehyde and increased the level of superoxide dismutase in the injured renal tissues, suggesting that the antioxidative capacity in the injured kidney was augmented by pioglitazone. Additionally, pioglitazone inhibited HIF-1α-dependent angiogenesis by down-regulating the expression of a panel of angiogenic factors. CONCLUSION: The current study demonstrates that pioglitazone benefits renal failure through activation of the antioxidative system and inhibition of angiogenesis in the injured kidney. Our study provides preliminary evidences for the potential application of this agent in the treatment of CKDs.


Subject(s)
Antioxidants/metabolism , Neovascularization, Physiologic/drug effects , PPAR gamma/agonists , Thiazolidinediones/pharmacology , Animals , Blood Urea Nitrogen , Creatinine/blood , Disease Models, Animal , Down-Regulation/drug effects , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Kidney/blood supply , Kidney/metabolism , Malondialdehyde/analysis , Nephrectomy , Nitric Oxide/analysis , PPAR gamma/metabolism , Pioglitazone , Rats , Rats, Sprague-Dawley , Renal Insufficiency, Chronic/drug therapy , Renal Insufficiency, Chronic/etiology , Superoxide Dismutase/analysis , Thiazolidinediones/therapeutic use , Vascular Endothelial Growth Factor A/blood , Vascular Endothelial Growth Factor A/metabolism
5.
Am J Nephrol ; 41(1): 28-36, 2015.
Article in English | MEDLINE | ID: mdl-25634106

ABSTRACT

AIMS: Vascular calcification is a risk factor for causing cardiovascular events and has a high prevalence among chronic kidney disease (CKD) patients. However, the molecular mechanism underlying this pathogenic process is still obscure. METHODS: Vascular smooth muscle cells (VSMCs) were induced by a concentration of phosphorus (Pi) of 2.5 mM, and were subjected to cell calcification analyses. The effect of high Pi on the Wnt/ß-catenin pathway was measured using a TOP/FOP-Flash reporter assay. The transcriptional regulation of ß-catenin on PIT1 (a type III sodium-dependent phosphate cotransporter) was confirmed by promoter reporter and chromatin immunoprecipitation assays. The 5/6 nephrectomized rat was used as an in vivo model and was fed a high Pi diet to induce aortic calcification. Serum levels of phosphate, calcium, creatine, and blood urea nitrogen were measured, and abdominal aortic calcification was examined. RESULTS: High Pi induced VSMC calcification, downregulated expression levels of VSMC markers, and upregulated levels of osteogenic markers. High Pi activated the Wnt/ß-catenin pathway and ß-catenin activity. ß-Catenin was involved in the process of high Pi-induced VSMC calcification. Further investigation revealed that ß-catenin transcriptionally regulated Pit1, a necessary player in VSMC osteogenic phenotype change and calcification. The in vivo study showed that ß-catenin was involved in rat abdominal aortic calcification induced by high Pi. When knockdown expression of ß-catenin in the rat model was investigated, we found that aortic calcification was reduced. CONCLUSION: These results suggest that ß-catenin is an important player in high phosphorus level-induced aortic calcification in CKD.


Subject(s)
Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolism , Phosphorus/pharmacology , Renal Insufficiency, Chronic/metabolism , Vascular Calcification/metabolism , Wnt Signaling Pathway , beta Catenin/metabolism , Actins/genetics , Actins/metabolism , Animals , Aorta , Blood Urea Nitrogen , Calcium/blood , Cells, Cultured , Core Binding Factor Alpha 1 Subunit/genetics , Core Binding Factor Alpha 1 Subunit/metabolism , Creatine/blood , Disease Models, Animal , Gene Expression Regulation , Gene Knockdown Techniques , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Male , Muscle, Smooth, Vascular/drug effects , Myocytes, Smooth Muscle/drug effects , Nephrectomy , Osteopontin/genetics , Osteopontin/metabolism , Phosphorus, Dietary/metabolism , Plasmalogens/blood , Rats , Rats, Sprague-Dawley , Sodium-Phosphate Cotransporter Proteins, Type III/genetics , Sodium-Phosphate Cotransporter Proteins, Type III/metabolism , Vascular Calcification/etiology , beta Catenin/genetics
6.
Int J Clin Exp Med ; 8(11): 21964-74, 2015.
Article in English | MEDLINE | ID: mdl-26885168

ABSTRACT

OBJECTIVE: The present study was designed to evaluate the role of mycobacterium tuberculosis early secretory antigen target-6 (MtbESAT-6) in the development of renal injury. METHODS: PET42a (+) ESAT6 prokaryotic expression plasmid was constructed and the purified ESAT6 protein without endotoxin was obtained. Sixty healthy, clean, male Kunming mice were randomly divided into two groups: the experimental group (n = 30) and the control group (n = 30). Each mouse in the experimental group were injected with 0.5 ml ESAT-6 protein, and each mouse in the control group were injected with 0.5 ml sterile saline on the tail vein. Blood, urine and kidney tissues were collected. Serum creatinine (Scr), blood urea nitrogen (BUN), and urinary creatinine (Cr) were determined by HITACHI 7150 automatic biochemical analyzer and creatinine clearance rate (Ccr) was calculated. Renal tissues were conducted for hematoxylin-eosin (HE) staining and pathological scores of renal injury were recorded under the light microscope. RESULTS: Using MTB H37Ra strains genome DNA as template, the ESAT6 gene amplified by Hieff Pfu DNA Polymerase using polymerase chain reaction (PCR) technique was consistent with the expected size. PET42a (+) ESAT6 vector plasmid was successfully obtained and ESAT6 recombinant protein was successfully expressed with the protein concentration of 1.69 mg/ml. BUN and Scr in the experimental group were gradually increased, Ccr was gradually decreased, and the pathological score of renal injury increased gradually, and all of which were significantly higher than that in the control group after the experiment of 12 h, 24 h and 48 h (all P < 0.05). CONCLUSION: MtbESAT-6 might contribute to the development of renal injury.

7.
ScientificWorldJournal ; 2014: 624573, 2014.
Article in English | MEDLINE | ID: mdl-25184149

ABSTRACT

OBJECTIVE: This meta-analysis aimed to investigate a comprehensive and reliable conclusion on the correlations of single nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor (VEGF) gene with the risk of diabetic nephropathy (DN) in patients with diabetes mellitus (DM). METHODS: We screened PubMed, Embase, Web of Science, Cochrane Library, CISCOM, CINAHL, Google Scholar, CBM, and CNKI databases for those relevant studies that investigated the association of 14,945 subjects with clinicopathological parameters in gastric cancer. RESULTS: Eleven case-control studies that met all inclusion criteria were included in this meta-analysis. A total of 14,945 subjects were involved, including 3,049 DN patients and 11,896 DM patients. Our meta-analysis results revealed that VEGF rs2010963 and rs3025039 polymorphisms might contribute to the risk of DN in DM patients. Ethnicity-stratified analysis suggested that VEGF genetic polymorphisms were associated with an increased risk of DN among Asians. However, we found no correlations of VEGF genetic polymorphisms with susceptibility to DN among Caucasians. CONCLUSION: Our findings suggest that VEGF rs2010963 and rs3025039 polymorphisms may contribute to the risk of DN in DM patients, especially among Asians. Thus, VEGF genetic polymorphisms could be useful biomarkers for early diagnosis of DN in DM patients.


Subject(s)
Diabetic Nephropathies/genetics , Genetic Predisposition to Disease , Polymorphism, Genetic , Vascular Endothelial Growth Factor A/genetics , Alleles , Genotype , Humans , Odds Ratio , Polymorphism, Single Nucleotide
8.
BMC Nephrol ; 15: 110, 2014 Jul 09.
Article in English | MEDLINE | ID: mdl-25012471

ABSTRACT

BACKGROUND: Therapeutic options in IgAN are still limited. The aim of this study is to explore the feasibility of using endothelial progenitor cell to treat IgAN in rat model. METHODS: Rat bone marrow mononuclear cells (BM-MNCs) obtained with density gradient centrifugation were cultured in vitro, and induced into endothelial progenitor cells (EPCs). EPCs were identified by surface marker CD34, CD133 and VEGFR2 (FLK-1) and by Dil-Ac-LDL/FITC-UEA-1 double staining. EPCs were labeled with PKH26 prior to transplantation. Rat model of IgAN was established by oral administration of bovine serum albumin together with lipopolysaccharide via the caudal vein and subcutaneous injection of CCL4. Kidney paraffin sections were stained by H&E and PAS. Immunofluorescence was used to assess IgA deposition in the glomeruli. Peritubular capillary (PTC) density was determined by CD31 staining. Monocyte chemoattrant protein-1 (MCP-1), hypoxia-inducible factor-1α (HIF-1α) and CD105 were also measured by immunohistochemistry, western blotting and real-time fluorescent quantitative PCR. RESULTS: The transplanted BM-EPCs were successfully located in IgAN rat kidney. After transplantation, Urinary red blood cell, urine protein, BUN, Scr and IgA serum level were significantly decreased, so were the areas of glomerular extracellular matrix and the IgA deposition in the glomeruli. In addition, PTC density was elevated. And the expression levels of HIF-1α and MCP-1 were significantly down-regulated, while the expression of CD105 was up-regulated. All these changes were not observed in control groups. CONCLUSION: The BM-EPCs transplantation significantly decreases the expansion of glomerular extracellular matrix and the deposition of IgA in the glomeruli; lowers the expression of inflammatory factors; increases PTC density; improves ischemic-induced renal tissue hypoxia, all of which improves the renal function and slows the progress of IgA nephropathy.


Subject(s)
Bone Marrow Transplantation/methods , Endothelial Progenitor Cells/transplantation , Glomerulonephritis, IGA/pathology , Glomerulonephritis, IGA/therapy , Animals , Cells, Cultured , Endothelial Progenitor Cells/physiology , Female , Glomerulonephritis, IGA/metabolism , Rats , Rats, Sprague-Dawley , Treatment Outcome
9.
Am J Nephrol ; 39(1): 75-84, 2014.
Article in English | MEDLINE | ID: mdl-24457259

ABSTRACT

AIMS: The optimal time for mesenchymal stem cell (MSCs) transplantation remains an unresolved issue. We compared the effects of MSCs on a rat remnant kidney model. METHODS: Male Sprague-Dawley rats were randomly divided and treated with a corresponding reagent at 4, 8, 12 and 16 weeks, respectively. A remnant kidney model was established and MSCs were injected into rats. The migration of MSCs was then assessed by using cell-tracking experiments. Renal function and histological analyses were performed 4 weeks after MSC transplantation. Immunohistochemistry, Western blotting and real-time polymerase chain reaction were used to detect the TGF-ß1 and α-SMA levels. RESULTS: Four weeks after MSC injection, MSCs were found to migrate to the injured kidney. Significant histological damage improvement was observed after the treatment of MSCs at 4 and 8 weeks. The functional benefits of MSC treatment were observed in the 5/6 nephrectomy (Nx) + MSC group and the benefits were significantly higher at 4 and 8 weeks than at other time points (p < 0.05). Meanwhile, serum creatinine and urea levels as well as glomerular sclerosis and tubulointerstitial injury indexes were decreased at 4 and 8 weeks. Compared with the 5/6 Nx + PBS group, TGF-ß1 and α-SMA levels were decreased in the 5/6 Nx + MSC group. CONCLUSION: These data can be used to optimize the MSC transplantation time point as a therapeutic modality.


Subject(s)
Kidney Transplantation/methods , Mesenchymal Stem Cells/cytology , Actins/metabolism , Animals , Cell Movement , Creatinine/blood , Fibrosis/therapy , Glomerular Filtration Rate , Glomerulosclerosis, Focal Segmental/blood , Kidney Tubules/injuries , Male , Rats , Rats, Sprague-Dawley , Time Factors , Transforming Growth Factor beta/metabolism , Urea/blood
10.
J Nephrol ; 26(3): 517-26, 2013.
Article in English | MEDLINE | ID: mdl-22684654

ABSTRACT

BACKGROUND: To investigate the pathogenesis of diabetic nephropathy (DN) and to search for novel therapeutic targets, the glomerular protein expression profile of KKAy mice treated by losartan was analyzed by two-dimensional differential gel electrophoresis (2D-DIGE). METHODS: The eight-week-old KKAy mice were divided into the losartan treatment group and the non-treatment group, and C57BL/6 mice were used as the control group. After 12 weeks treatment, glomeruli were isolated by abdominal perfusion with magnetic beads, and the glomerular proteins were extracted. The glomerular protein expression profiles were investigated using 2D-DIGE and MALDI-TOF mass spectrometry. Western blot analysis was used to confirm the results of proteomics. RESULTS: Losartan treatment improved albuminuria and renal pathologic lesion of KKAy mice. A total of 62 glomerular proteins were differentially expressed between the KKAy losartan treatment mice and KKAy non-treatment mice. Among them, the expression of 28 proteins were up-regulated, including glycerokinase, sulfite oxidase, glycine amidinotransferase, and adenosylhomocysteinase. The expression of 13 proteins were down-regulated, including 3-mercaptopyruvate sulfurtransferase, ATP synthase subunit d, 60 kDa heat shock protein, and 75 kDa glucose-regulated protein(GRP75). A total of six proteins were found to be differentially expressed between the KKAy non-treatment mice and C57BL/6 mice glomeruli, and their differential expression was suppressed by losartan treatment, including mitochondrial ATP synthase subunit d, GRP75, and selenium-binding protein 1 et al. CONCLUSIONS: Treatment with losartan suppresses the differential expression of mitochondrial ATP synthase subunit d, GRP75, selenium-binding protein 1 etc. In diabetic KKAy mice glomeruli, may play a renoprotective role by reducing glomerular mitochondrial ROS genesis and inhibiting oxidative stress.


Subject(s)
Angiotensin II Type 1 Receptor Blockers/pharmacology , Diabetes Mellitus, Type 2/metabolism , Diabetic Nephropathies/metabolism , Kidney Glomerulus/drug effects , Kidney Glomerulus/metabolism , Losartan/pharmacology , Protein Biosynthesis/drug effects , Animals , Male , Mice , Mice, Inbred C57BL
11.
Kidney Blood Press Res ; 38(1): 11-20, 2013.
Article in English | MEDLINE | ID: mdl-24503496

ABSTRACT

BACKGROUND/AIMS: The aim of our study was to reveal the role of CD44-Hyaluronic acid (HA) in the homing and improving renal function of systemically transplanted MSCs in chronic renal failure. METHODS: First, a remnant kidney model was established in rats and the expression of HA was determined using immunohistochemistry (IHC) and western blotting. Next, chemotaxis assay using flow cytometry, and cell migration assay of MSCs were performed in vitro. Then, MSCs were transplanted into rats, thus, sprague-Dawley (SD) rats were randomly divided into sham group, 5/6 nephrectomy (5/6 Nx) group, MSC group and MSC/Anti-CD44 group (n = 8 for all groups). Migration of MSCs to the kidney in these rats was assessed by using cell tracking experiments, and tissue damage was evaluated by morphological analysis using Masson's trichrome staining and periodic acid Schiff staining. RESULTS: HA was significantly observed in 5/6 Nx group, but not in sham group. Meanwhile, HA was discovered induced MSCs migration remarkably (p < 0.05) and anti-CD44 antibody inhibited the migration significantly (p < 0.05) in vitro. In vivo, the GFP-MSCs were observed in MSC group and the cells reduced in MSC/Anti-CD44 groups, especially, in the tubulointerstitium. CONCLUSION: Our findings reveal that CD44-HA has the potential to induce MSCs homing to injured tissue, while its effect on the ability of MSCs, improving tissue function, is not significant.


Subject(s)
Hyaluronan Receptors/pharmacology , Hyaluronic Acid/pharmacology , Kidney Diseases/therapy , Kidney/cytology , Mesenchymal Stem Cell Transplantation/methods , Animals , Cell Movement/drug effects , Creatinine/blood , Kidney/drug effects , Kidney Cortex/cytology , Kidney Diseases/blood , Kidney Diseases/physiopathology , Male , Nephrectomy , Rats , Rats, Sprague-Dawley , Urea/blood
12.
Kidney Blood Press Res ; 36(1): 209-19, 2012.
Article in English | MEDLINE | ID: mdl-23147235

ABSTRACT

BACKGROUND/AIMS: The aim of this study was to investigate the effect of netrin-1 on peritubular capillary (PTC) loss and hypoxia in 5/6 nephrectomized (Nx) rats. METHODS: Male Sprague-Dawley rats were divided into three groups (n = 10 rats/group): sham-operated rats treated with control adenovirus; 5/6 Nx rats treated with control adenovirus; and 5/6 Nx rats treated with recombinant adenovirus mediated netrin-1 gene (Ad-netrin-1) therapy. Rats were killed 12 weeks after surgery. Blood urea nitrogen (BUN), serum creatinine (Scr) and 24-h urinary albumin excretion rates were measured. Pathological changes in renal tissues were analyzed histologically. The concentration of netrin-1, CD34, and hypoxia-inducible factor-1α (HIF-1α) were analyzed by immunohistochemistry, Western blotting and real-time PCR. RESULTS: Renal function and histopathological damage were significantly improved in Adnetrin-1 treated 5/6 Nx rats, compared with rats treated with the control adenovirus in the 5/6 Nx group. Furthermore, Ad-netrin-1 treatment induced a significant increase in renal PTC density, accompanied by a significant decrease in HIF-1α expression. CONCLUSION: Adenovirus mediated netrin-1 treatment attenuates PTC damage, relieves tissues hypoxia and improves renal function, thus alleviating renal pathological changes and interstitial fibrosis in 5/6 Nx rats.


Subject(s)
Capillaries/physiopathology , Hypoxia/prevention & control , Kidney Tubules/blood supply , Kidney Tubules/physiopathology , Neovascularization, Pathologic/prevention & control , Nephrectomy , Nerve Growth Factors/therapeutic use , Tumor Suppressor Proteins/therapeutic use , Adenoviridae/genetics , Animals , Antigens, CD34/metabolism , Disease Models, Animal , Disease Progression , Genetic Therapy , Hypoxia/physiopathology , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Kidney Diseases/metabolism , Kidney Diseases/physiopathology , Kidney Diseases/therapy , Kidney Tubules/metabolism , Male , Neovascularization, Pathologic/physiopathology , Nerve Growth Factors/genetics , Nerve Growth Factors/metabolism , Netrin-1 , Rats , Rats, Sprague-Dawley , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism
13.
Mol Cell Biochem ; 368(1-2): 137-45, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22661380

ABSTRACT

Chronic aristolochic acid (AA) nephropathy (CAAN) caused by intake of AA-containing herbs is difficult to treat. We evaluated the therapeutic effect of bone marrow (BM) mesenchymal stem cells (MSCs) on a rat model of CAAN. Female Wistar rats were fed with decoction of Caulis Aristolochia manshuriensis by intragastric administration. MSCs were prepared from BM of male Wistar rats and injected into female CAAN rats through tail vein. Body weight, renal function, and urinary excretion of these CAAN rats were monitored before killing at the end of the 20th week. Blood, urine, and tissue samples were collected from experimental (MSC and non-MSC) and normal control groups. All animals developed renal fibrosis after 12 weeks of intake of AA-containing decoction. Fibrosis in the MSC groups was significantly reduced as examined with light and electron microscopy. Blood urea nitrogen, serum creatinine, and urine protein levels were significantly reduced and hemoglobin levels were improved in the MSC group as compared with the non-MSC group (p < 0.01). The expression of TGF-ß1 mRNA and protein was reduced but hepatic growth factor (HGF) was increased in the MSC group compared with the non-MSC group, but still higher than the normal control level as measured by immunochemical, RT-PCR, and western blotting assays (p < 0.01). The renal fibrosis of CAAN could be protected by isogenic MSC transplantation, probably via upregulation of HGF and downregulation of TGF-ß1.


Subject(s)
Aristolochic Acids/adverse effects , Bone Marrow Cells/metabolism , Down-Regulation , Hepatocyte Growth Factor/biosynthesis , Kidney Diseases/chemically induced , Kidney Diseases/therapy , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/metabolism , Transforming Growth Factor beta1/biosynthesis , Up-Regulation , Animals , Aristolochia , Aristolochic Acids/chemistry , Aristolochic Acids/pharmacology , Bone Marrow Cells/ultrastructure , Female , Fibrosis , Kidney Diseases/pathology , Male , Mesenchymal Stem Cells/ultrastructure , Rats , Rats, Wistar , Transplantation, Isogeneic
14.
Clin Nephrol ; 77(6): 505-9, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22595395

ABSTRACT

BACKGROUND: Venous thrombosis is common in nephrotic syndrome, but portal vein thrombosis has a relatively low incidence in patients with nephrotic syndrome. We describe here a case of an 18-year old male student with newly diagnosed nephrotic syndrome that was complicated with portal, splenic and superior mesenteric vein thrombosis. CONCLUSION: In the presence of newly diagnosed nephrotic syndrome of minimal change disease, thrombus formation can occur and should be noted, particularly when it occurs, in rare sites. The recognition in nephrotic syndrome complicated with portal, splenic and superior mesenteric vein thrombosis should be emphasized.


Subject(s)
Mesenteric Vascular Occlusion/etiology , Nephrosis, Lipoid/complications , Portal Vein , Splenic Vein , Venous Thrombosis/etiology , Adolescent , Humans , Immunosuppressive Agents/therapeutic use , Male , Mesenteric Vascular Occlusion/diagnosis , Mesenteric Vascular Occlusion/drug therapy , Mesenteric Veins/diagnostic imaging , Nephrosis, Lipoid/diagnosis , Nephrosis, Lipoid/drug therapy , Phlebography/methods , Portal Vein/diagnostic imaging , Splenic Vein/diagnostic imaging , Thrombolytic Therapy , Tomography, X-Ray Computed , Treatment Outcome , Venous Thrombosis/diagnosis , Venous Thrombosis/drug therapy
15.
Acta Pharmacol Sin ; 32(8): 1025-30, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21765447

ABSTRACT

AIM: To investigate whether aristolochic acid (AA) induced the apoptosis of human umbilical vein endothelial cells (HUVECs) in vitro and the underlying mechanism. METHODS: HUVECs were treated with AA (5, 10 or 20 µg/mL) for 12, 24 and 48 h. Cell viabilities were determined with MTT assay. Hoechst 33258 staining and flow cytometry were used to examine the apoptosis of HUVECs. Western blotting was used to evaluate Akt phosphorylation. Bcl-2 and Bax levels were measured using Western blotting and RT-PCR assays. RESULTS: Treatment of HUVECs with AA significantly decreased the cell viabilities in dose- and time-dependent manners. Morphological changes of apoptosis were observed in AA-treated cells. AA inhibited Akt activation, which was attenuated by pretreatment of the cells with LY294002 (20 µmol/L) or wortmannin (50 nmol/L). Furthermore, AA reduced Bcl-2 levels and increased Bax levels. CONCLUSION: AA induces apoptosis of HUVECs in vitro via the PI3K/Akt signaling pathway and by modulating the ratio Bcl-2 and Bax.


Subject(s)
Apoptosis/drug effects , Aristolochic Acids/pharmacology , Human Umbilical Vein Endothelial Cells/drug effects , Human Umbilical Vein Endothelial Cells/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Cells, Cultured , Humans , Signal Transduction/drug effects
16.
Biol Pharm Bull ; 33(5): 768-72, 2010.
Article in English | MEDLINE | ID: mdl-20460752

ABSTRACT

Probucol is a cholesterol-lowering drug with an anti-proliferative effect. Excessive growth of glomerular mesangial cells and overexpression of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF) are the pathological features of diabetic nephropathy. In this study, human mesangial cells (HMCs) treated with high glucose showed the above-mentioned features through the activation of Janus kinase 2 (JAK2)/signal transducers and activators of transcription (STAT) pathway. Probucol can suppress cell proliferation, down-regulate mRNA and protein levels of TGF-beta1 and CTGF in HMCs treated with high glucose. Phosphorylation of JAK2, STAT1 and STAT3 caused by high glucose was obviously prevented in HMCs pretreated with probucol, indicating that the protective effect of probucol on HMCs might be through the inhibition of JAK2/STAT pathway. Therefore, probucol could be a potential therapeutic agent for diabetic nephropathy, and this paper provides new insights into the molecular mechanisms underlying probucol's effects.


Subject(s)
Antioxidants/pharmacology , Gene Expression Regulation/drug effects , Hyperglycemia/drug therapy , Janus Kinase 2/metabolism , Mesangial Cells/drug effects , Probucol/pharmacology , STAT Transcription Factors/metabolism , Antioxidants/therapeutic use , Cell Line , Cell Proliferation/drug effects , Connective Tissue Growth Factor/genetics , Connective Tissue Growth Factor/metabolism , Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/metabolism , Down-Regulation , Glucose/pharmacology , Humans , Hyperglycemia/metabolism , Mesangial Cells/metabolism , Phosphorylation , Probucol/therapeutic use , RNA, Messenger/metabolism , STAT1 Transcription Factor/metabolism , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Transforming Growth Factor beta1/genetics , Transforming Growth Factor beta1/metabolism
18.
Zhonghua Yi Xue Za Zhi ; 88(10): 705-10, 2008 Mar 11.
Article in Chinese | MEDLINE | ID: mdl-18642775

ABSTRACT

OBJECTIVE: To investigate the potentiality of mesenchymal stem cells (MSCs) to differentiate into vascular endothelia cells (ECs) in peritubular capillary (PTC) in chronic aristolochic acid nephropathy (CAAN). METHODS: MSCs were isolated from a male Wistar rat. The surface markers were identified with flow cytometry. Thirty female Wistar rats were randomly divided into 3 equal groups: Group A, perfused intragastrically with decoction of Caulis Aristolochiae manshuriensis for 12 weeks to establish CAAN models, Group B, perfused intragastrically with decoction of Caulis Aristolochiae manshuriensis for 12 weeks to establish CAAN models and injected with the MSCs by caudal vein in the 12th week, and Group C, perfused intragastrically with drinking water for 12 weeks and then injected with normal saline by caudal vein to be used as normal controls. At week 16, specimens of blood and urine were collected to detect the blood urea nitrogen (BUN), serum creatinine (Scr) and urine protein, and then the rats were killed with their kidneys taken out. Sex-determining region of the Y chromosome-fluorescence in situ hybridization (SRY-FISH) test with carboxyfluorescein (FAM)- was used to detect the cells originated from the source of the male donors. Immunohistochemistry was used to detect CD34, marker antigen pf EC. HE and Masson staining and electron microscope were used to observe the pathology of the kidney. Immunohistochemistry and RT-PCR were used to detect the expression of vascular endothelial growth factor (VEGF). Correlation analysis was conducted to study the relationships among these indices. RESULTS: Y chromosome and CD34 double positive cells could be seen in the renal tissue of Group B. At week 16, the density of PTC and integrated optical density of VEGF of Group A were (5.3 +/- 0.8)/0.13 mm2 and (2.8 +/- 0.4) x 10(3) respectively, both significantly lower than those of Group B [(26.5 +/- 1.6)/0.13 mm2 and (14.7 +/- 1.7) x 10(3) respectively, both P < 0.011]. The Scr and urine protein of Group A were significantly higher than those of Group B. The expression of VEGF mRNA of Group A was significantly lower than that of Group B. CONCLUSION: MSCs can differentiate into ECs. MSCs transplantation has beneficial effects on CAAN, which is possibly related with the reduction of PTC.


Subject(s)
Bone Marrow Cells/cytology , Cell Differentiation , Mesenchymal Stem Cells/cytology , Animals , Aristolochic Acids/toxicity , Endothelial Cells/cytology , Endothelium, Vascular/cytology , Kidney Diseases/chemically induced , Kidney Tubules/blood supply , Male , Rats , Rats, Wistar
19.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 28(2): 146-51, 2008 Feb.
Article in Chinese | MEDLINE | ID: mdl-18386579

ABSTRACT

OBJECTIVE: To investigate the potential effect of homologous bone marrow mesenchymal stem cells (MSCs) on repairing peri-tubular capillary cluster (PTCC), and on improving renal tubular and mesenchymal hypoxia condition. METHODS: Monocyte was purified from bone marrow, amplified and identified as MSCs in vitro. Thirty female Wistar rats were randomly divided into 3 groups, the normal control group (Group A), MSCs transplanted group (Group B) and un-transplanted group (Group C). Rats in Group A was administered with drinking water by gastrogavage for 12 weeks, while those in Group B and C were administered with Aristolochia Decoction for 12 weeks to establish chronic aristolochic acid nephropathy (CAAN) model. At the end of the 12th week, 1 ml of MSCs was injected through caudal vein to the rats in Group B, while to those in Group A and C normal saline was injected instead. Blood, urine and kidney tissue of rats were collected at the end of the 16th week for examination, and their kidney tissue were made into serial section for determining the distribution of Y chromosome and CD34 double positive cells, and the pathological, immunohistochemical changes were observed using Western blotting and RT-PCR, etc. RESULTS: Y chromosome and CD34 double positive cells could be seen in MSCs transplanted renal tissue in group B. At the end of the 16th week, the PTCC density in Group C and B was (26.47 +/- 1.56)/ 0.13 mm2 and (5.26 +/- 0.78)/0.13 mm2 respectively, and the IOD value of hypoxia inducible factor-1alpha (HIF-1alpha) in them was (6.74 +/- 0.67) x 10(3) and (25 27 +/- 1.46) x 10(3) respectively, all showing significant difference between the two groups (P < 0.01). The content of CD34 was higher in Group B than that in Group C (P < 0.01). CONCLUSION: Homologous MSCs can enhance the vascular endothelial cells differentiation to repair the PTCC, thus to improve the renal tubular and mesenchymal hypoxia status.


Subject(s)
Bone Marrow Transplantation/methods , Kidney Diseases/surgery , Kidney Tubules/blood supply , Mesenchymal Stem Cell Transplantation/methods , Animals , Antigens, CD34/biosynthesis , Antigens, CD34/genetics , Aristolochic Acids , Blotting, Western , Bone Marrow Cells/cytology , Capillaries/abnormalities , Capillaries/metabolism , Endothelial Cells/metabolism , Endothelial Cells/pathology , Female , Immunohistochemistry , Kidney Diseases/chemically induced , Kidney Diseases/pathology , Kidney Tubules/pathology , Male , Mesenchymal Stem Cells/cytology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Random Allocation , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Transplantation, Homologous
20.
Am J Nephrol ; 26(4): 363-71, 2006.
Article in English | MEDLINE | ID: mdl-16873992

ABSTRACT

BACKGROUND/AIMS: To investigate the effects of peritubular capillary (PTC) loss and hypoxia on the progression of tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy (AAN). METHODS: Female Wistar rats received Caulis aristolochiae manshuriensis (CAM) decoction by gavage for 8 weeks, and were sacrificed at 8, 12 and 16 weeks, respectively, after administration. Blood urea nitrogen (BUN), serum creatinine (Scr) and urinary protein were monitored prior to sacrifice. PTC loss and tubulointerstitial hypoxia were assessed by CD34 immunostaining and hypoxia-inducible factor-alpha subunit 1 (HIF-1alpha) expression, respectively. Myofibroblasts were assessed by alpha-smooth muscle actin (alpha-SMA) expression. The expression of angiogenic factor was assessed by vascular endothelial growth factor (VEGF). RESULTS: AAN rats differed from controls by increased BUN, Scr and 24-hour urinary protein excretion rates. There was a progressive loss of PTCs in the AAN model, which was associated with the decreased expression of VEGF. A significant increase in nuclear localization of HIF-1alpha was seen 16 weeks after treatment with CAM decoction in the context of severe tubulointerstitial damage. Multifocal tubulointerstitial fibrosis was seen in AAN rats at weeks 12 and 16, predominantly in the area of the outer stripe and outer medulla. No significant pathologic changes were found in control rats. CONCLUSION: Following the reduction of PTCs density and up-regulation of HIF-1alpha, the tubulointerstitial fibrosis area increased. Ischemia and hypoxia are the important causes of severe tubulointerstitial fibrosis in AAN rats.


Subject(s)
Aristolochic Acids/adverse effects , Capillaries/pathology , Drugs, Chinese Herbal/adverse effects , Hypoxia/pathology , Kidney Tubules/blood supply , Kidney Tubules/pathology , Nephritis, Interstitial/pathology , Animals , Capillaries/drug effects , Capillaries/physiopathology , Disease Models, Animal , Disease Progression , Female , Fibrosis , Hypoxia/chemically induced , Hypoxia/physiopathology , Kidney Tubules/drug effects , Nephritis, Interstitial/chemically induced , Nephritis, Interstitial/physiopathology , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...